Literature DB >> 21185575

[Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].

Antonio Naranjo1, Soledad Ojeda-Bruno, Félix Francisco-Hernández, Celia Erausquin, Iñigo Rúa-Figueroa, Carlos Rodríguez-Lozano.   

Abstract

BACKGROUND AND OBJECTIVES: There are different guidelines for secondary prevention of fractures related with osteoporosis. Our aim is to analyse the appliance of such guidelines in a sample of patients with fragility fracture PATIENTS AND METHODS: Adult patients older than 50 years attended in the emergency department with a fragility fracture were invited to participate in a study for secondary prevention. Clinical data and densitometry for the FRAX index were recorded. Current guidelines were employed to calculate the number of patients who needed secondary prevention.
RESULTS: With the appliance of current guidelines to 380 patients, 54-100% of women and 26-81% of men were candidates for treatment. For hip fractures the percentage was 81-100% and for forearm fractures 36-93%. FRAX index for hip fracture was ≥3% in 35% of patients. The National Institute for Health and Clinical Excellence and the National Osteoporosis Foundation 2009 were the most restrictive guidelines (54% and 57% respectively). On the other hand the National Guideline Clearinghouse (87%) and the National Osteoporosis Guideline Group (93%).
CONCLUSION: There are high differences in the percentage of patients who need treatment to prevent new fractures according to the guidelines. Fewer patients require treatment when the FRAX index is included in a guideline.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185575     DOI: 10.1016/j.medcli.2010.06.028

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  Changing trends in the epidemiology of hip fracture in Spain.

Authors:  R Azagra; F López-Expósito; J C Martin-Sánchez; A Aguyé; N Moreno; C Cooper; A Díez-Pérez; E M Dennison
Journal:  Osteoporos Int       Date:  2013-12-10       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.